<DOC>
	<DOCNO>NCT00557973</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety treatment XP19986 Sustained Release ( SR ) Tablet compare placebo subject spasticity due spinal cord injury</brief_summary>
	<brief_title>A Safety Efficacy Study XP19986 Subjects With Spasticity Due Spinal Cord Injury</brief_title>
	<detailed_description>This multiple-dose , randomize , placebo-controlled crossover study efficacy safety XP19986 SR1 subject spasticity due spinal cord injury . Three cohort subject randomize receive XP19986 SR1 10 mg every 12 hr 20 mg every 12 hr 30 mg every 12 hr one treatment segment placebo every 12 hr alternate treatment segment . Each subject serf control cross-over study .</detailed_description>
	<mesh_term>Spinal Cord Injuries</mesh_term>
	<mesh_term>Muscle Spasticity</mesh_term>
	<mesh_term>Arbaclofen placarbil</mesh_term>
	<mesh_term>Baclofen</mesh_term>
	<criteria>Spasticity secondary traumatic spinal cord injury C5 T12 spinal cord level , least 12 month postinjury stable neurological deficit Traumatic brain injury cognitive deficit etiology may influence compliance study procedures outcome measure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>